Investigation of the levels of oxidative stress parameters in HIV and HIV-TB co-infected patients

Olufunsho Awodele¹, Sunday O. Olayemi¹, Joseph A. Nwite¹, Titilope A. Adeyemo²

¹Department of Pharmacology, College of Medicine, University of Lagos, Lagos, Nigeria
²Department of Haematology and Blood Transfusion, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria

Abstract

Introduction: Among opportunistic pathogens associated with acquired immunodeficiency syndrome (AIDS), Mycobacterium tuberculosis is distinguished by its relative virulence and potential for person-to-person transmission. Oxidative stress is associated with TB infection with a high level in patients with HIV-TB co-infection. However, the comparative level of oxidative stress in HIV patients on highly active anti-retroviral therapy (HAART) and naïve (untreated) HIV patients is not clear.

Methodology: This study is aimed to determine the level of oxidative stress and haematological parameters in HIV patients (naïve), HIV patients undergoing HAART, and HIV-TB co-infected patients. In total, 100 consenting subjects were recruited from the AIDS Prevention Initiative in Nigeria (APIN) Clinic. For controls, normal male healthy volunteers were recruited from the blood donor clinic and females from the APIN clinic staff members, both of the Lagos University Teaching Hospital. Measurements of antioxidant enzyme activity and lipid peroxidation were performed according to standard procedures. Haematological parameters were determined using a fully automated hematology analyzer.

Results: Red blood cells significantly decreased (P≤0.001) in all patients when compared with control subjects. The lipid peroxidation (MDA) was significantly high (P≤0.05) in naïve patients when compared to HIV patients on HAART. The decrease in the levels of GSH in both naïve and HIV-TB co-infected patients (P≤0.001) and HIV patients on HAART (P<0.05) were significant when compared to control patients.

Conclusion: There is lower antioxidant level and higher MDA in naïve and HIV-TB co-infected patients as compared to HIV patients on HAART and the seronegative patients.

Key words: HIV untreated; HIV treated; HAART; HIV-TB co-infection; oxidative stress; haematological parameters


(Received 04 February 2011 – Accepted 12 March 2011)

Copyright © 2012 Awodele et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Introduction

Acquired immunodeficiency syndrome (AIDS) is a fatal illness caused by a retrovirus known as the human immunodeficiency virus (HIV) that breaks down the body’s immune system, infects CD4⁺ cells initially, and progressively leads to AIDS [1]. Among the opportunistic pathogens associated with AIDS, Mycobacterium tuberculosis is distinguished by its relative virulence and potential for person-to-person transmission [2,3]. Persons infected with HIV are particularly susceptible to tuberculosis, both from the reactivation of latent infection and from new infection with rapid progression to active disease [2,3].

In 2008, more than one-third of HIV-infected individuals were also infected with tuberculosis (TB) bacteria [4]. In 2007, of the 9.3 million new TB cases, 1.4 million were also living with HIV. In many parts of the world TB is a leading killer of HIV-infected individuals and 500,000 HIV positive TB patients died in 2007 [5,6]. It is widely reported that oxidative stress, an imbalance between production and elimination of chemically reactive species, such as reactive oxygen species (ROS) [7], is involved in HIV infection [8]. Viral Tat protein induces an enhanced ROS production in HIV-infected patients by mitochondrial generation of superoxide anion [9], which in turn may activate nuclear factor κB (NF-κB) [8], thus increasing HIV transcription. Oxidative stress also has been shown to be associated with TB infection through activation of phagocytes by mycobacteria which may further contribute to immunosuppression [10,11]. Furthermore, an earlier report [12] has shown high levels of oxidative stress.
in HIV-TB co-infected patients. A variety of enzymatic (superoxide dismutase, catalase, glutathione peroxidase, etc.) and nonenzymatic (ascorbate, etc.) antioxidants present in human serum become insufficient to circumvent HIV-1 replication secondary to cellular ROS production (superoxide anion, hydroxyl radical, hydrogen peroxide etc.) by a pro-oxidant effect of inflammatory cytokines and/or a polymorphonuclear leukocyte activation [13].

Friis-Moller et al. [14] have shown that HIV-infected patients are in oxidative imbalance early in the disease; serum and tissue anti-oxidants levels are low and peroxidation products elevated. High plasma levels of malondialdehyde (MDA), reduced plasma glutathione (GSH), and decreased superoxide dismutase (SODs) activities are normally found. HIV and TB infection also result in considerably reduced vitamin C concentrations [15]. Formation of free radicals from mitochondrial leakage due to increased oxygen consumption, inflammatory and reperfusion processes, and leukocyte activation elevate oxidative stress in erythrocytes [16].

The pathogenesis of immunodeficiency during chronic HIV infection includes apoptosis of CD4 T cells that is influenced by ROS production [17]. Valcour and Shiramizu [18] have in their work indicated that an increased level of ROS may also increase blood-brain barrier permeability and contribute to HIV-associated dementia. Access to potent antiretroviral therapy (ART) decreases morbidity and mortality due to HIV infection and AIDS [19] and has made HIV infection a manageable chronic illness. Unfortunately, many patients who are prescribed chronic ART experience drug toxicities that include metabolic, hepatic, neurological and cardiovascular complications [20].

Highly active anti-retroviral therapy (HAART) may increase chemically reactive species in circulation, possibly by producing more oxidized metabolites deriving from the interaction between ROS and infected-cell biomolecules [21-23]. This is supported by several biochemical mechanisms, such as mitochondrial interference, following treatment with HAART-NRTI (nucleoside reverse transcriptase inhibitors) [22], and activation of the P380 hepatic system by HAART, which are protease inhibitors (PI) [21]. A putative mechanism of these toxicities includes inhibition of mitochondrial DNA polymerase-γ, with resultant mitochondrial DNA depletion and tissue-specific mitochondrial dysfunction [24]. Other metabolic toxicities such as dyslipidemia and insulin resistance appear to be predominately associated with protease inhibitor (PI) exposure, likely through effects on lipid metabolism and cellular glucose uptake, respectively. [20]. Although specific mechanisms of ART-associated toxicities are largely unknown, Day and Lewis [15] showed that all of these processes may be mediated at a fundamental level by free radical-induced cellular damage, also referred to as oxidant stress. Montine et al. [25] and Shishehbor et al. [26] independently described oxidant stress as an underlying pathogenic mechanism during various human disease conditions including cardiovascular and neurodegenerative diseases.

In view of the above considerations, this study aimed to determine the oxidative stress and haematological parameters in HIV patients (naïve, who have not started HAART treatment), HIV patients undergoing HAART treatment, and HIV-TB co-infected patients. The findings obtained from this study will further enhance our understanding of the level of oxidative stress in HIV patients who have not been treated and the effect of HAART on oxidative stress in HIV patients undergoing treatment.

Methodology

Study site

The study was conducted at the AIDS Prevention Initiative in Nigeria (APIN) Clinic in Lagos University Teaching Hospital, Lagos, Nigeria, which is one of the treatment centers for the HIV relief program in Nigeria. The clinic runs from 8:00 a.m. to 4:00 p.m. (Monday to Friday) and has about 10,000 registered patients.

Subjects

A total of 100 consenting subjects (45 males, 55 females), aged 18 to 40 years were involved in this study. The subjects were comprised of normal human volunteers (NHV, n = 25), HIV naïve patients (n = 25), HIV patients on HAART treatment (n = 25) and HIV-TB co-infected patients on treatment with HAART and anti-tuberculous therapy (ATT), (HIV/TB, n = 25). The patients were recruited from the AIDS Prevention Initiative in Nigeria (APIN) Clinic. The normal human healthy volunteers (males) were recruited from the blood donor clinic and (females) from the APIN clinic staff members, both of the Lagos University Teaching Hospital (LUTH), Lagos, Nigeria.
Ethical approval and patient consent

Ethical approval was obtained from the Research and Ethics Committee of Lagos University Teaching Hospital, (LUTH), Lagos, Nigeria. Patient consent was obtained and the details of the study explained to each individual subject before sample collection was done.

Eligibility

Patients with complications such as renal, endocrine or hepatic diseases, diabetes mellitus, obesity, viral and/or bacterial infections were excluded from the study. An age bracket of between 18 and 40 years was employed to avoid having results affected by factors of old age which has also been shown to be associated with oxidative stress.

Blood samples

From each volunteer, 10ml of venous blood was collected as follows: 5 ml in Na-EDTA for full blood count and 5 ml in a heparinized vacutainer for the oxidative stress parameters. Plasma was extracted by centrifuging the heparinized whole blood in a Whisperfuge centrifuge Model 684 (GEA Westfalia, Northvale, NJ, USA) at 2500 revolutions for 10 minutes and used for the analysis of malondialdehyde (MDA), vitamin C, reduced glutathione (GSH), superoxide dimutase (SOD), and catalase. The plasma for enzyme analysis was stored at -83°C before the analysis was done.

Measurement of haematological parameters, antioxidant enzymes and lipid peroxidation

The red blood cell count (RBC), total white blood cell count (WBC), platelet count, total hemoglobin and hematocrit were determined using an automated haematology analyzer (Pentra-XL 80, Horiba ABX, Kyoto, Japan). The CD4+ lymphocyte count was estimated by a Fluorescence Activated Cell Sorter (FACS) count system (Becton Dickinson, Franklin Lakes, NJ, USA).

Measurements of antioxidant enzyme activity and lipid peroxidation were performed according to standard procedures: catalase [27-29]; superoxide dismutase (SOD) [29]; malondialdehyde (MDA) [29, 30]; reduced glutathione (GSH) and Glutathione-S-transferase (GST) were determined using the methods of Beers and Seizer [27] and Beuge and Aust [28].

Statistical analysis

The results are presented as mean ± standard error of the mean (SEM). Statistical significance between the groups was analyzed by means of the student t-test and Tukey’s multiple comparison test. P values less than 0.05 were considered significant.

Results

Standard treatment guidelines were used to place all the categories of patients on the appropriate therapeutic regimen. The HIV patients on HAART treatment were placed on either a combination of two nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, tenofovir) and one non nucleoside reverse transcriptase inhibitor (nevirapine and efavirenz) or two nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, tenofovir) and two protease inhibitors (lopinavir and ritonavir). The HIV-TB co-infected patients were placed on a fixed dose of combined (FDC) antituberculous agents (rifampicin, isoniazid, parazinamide, ethambutol) together with the HAART treatment. However, nevirapine and lopinavir were avoided from the therapy of this category of patients because of its established drug-drug interaction and adverse effects.

Table 1 shows the demographics of the study group as follows: the mean age (in years) of normal human volunteers was 28.60 ± 6.11, of HIV-infected patients not on HAART 33.48 ± 3.11, of HIV-infected patients on HAART 35.52 ± 4.11 and of HIV-TB co-infected patients on treatment 32.84 ± 6.12. The sex distribution (male:female) was 40:60 in NHV and naïve patients, 56:44 in HIV patients on HAART, and 48:52 in HIV-TB co-infected patients.

Table 2 shows that the levels of CD4* cell count and total RBC count were significantly decreased (P ≤ 0.001) in all categories of patients when compared with control subjects. There was also a significant decrease (P ≤ 0.05) in haemoglobin and hematocrit of the HIV-TB co-infected patients when compared with the control group. The results also show a significant (P < 0.05) reduction in the white blood cell counts between the HIV (HAART) and naïve patients. The platelets results show a significant (P ≤ 0.05) increase between HIV-TB co-infected patients and naïve and control patients.

The levels of plasma protein were significantly (P ≤ 0.001) increased in naïve and HIV-TB co-infected patients compared to the NHV subjects (Table 3). Protein results also showed a significant (P ≤ 0.01) decrease among the HIV (HAART), HIV-TB co-infected, and naïve patients. The lipid peroxidation (MDA) was significantly high (P ≤ 0.05) in naïve patients when compared to those of HIV-infected patients on HAART and control subjects. The
Table 1. Demographic Characteristics of studied subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NHV</th>
<th>Naive</th>
<th>HIV (HAART)</th>
<th>HIV-TB co-infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of Subjects</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Sex (M:F)%</td>
<td>40:60</td>
<td>40:60</td>
<td>56:44</td>
<td>48:52</td>
</tr>
<tr>
<td>Age (Mean ± SD) yrs</td>
<td>28.60 ± 6.11</td>
<td>33.48 ± 3.11</td>
<td>35.52 ± 4.11</td>
<td>32.84 ± 6.12</td>
</tr>
</tbody>
</table>

NHV (Normal Human Volunteers), Naive (HIV patients not on HAART), HIV (HIV patients on HAART), HIV-TB co-infection on treatment

Table 2. Haematological parameters of HIV and HIV-TB patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NHV</th>
<th>Naive</th>
<th>HIV (HAART)</th>
<th>HIV-TB co-infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBC(10⁶/µl)</td>
<td>4.88 ± 0.24</td>
<td>4.03 ± 0.11***</td>
<td>3.76 ± 0.12***</td>
<td>3.76 ± 0.06***</td>
</tr>
<tr>
<td>WBC(10⁶/µl)</td>
<td>5.51 ± 0.25</td>
<td>6.78 ± 0.45</td>
<td>4.68 ± 0.30 a</td>
<td>5.72 ± 0.46</td>
</tr>
<tr>
<td>CD4+count (cell/ µl)</td>
<td>775.20 ± 28.06</td>
<td>157.36 ± 48.49***</td>
<td>300.90 ± 38.36*** a</td>
<td>300.80 ± 31.10*** a</td>
</tr>
<tr>
<td>Haemoglobin (g/dl)</td>
<td>12.80 ± 0.54</td>
<td>11.13 ± 0.40</td>
<td>11.58 ± 0.64</td>
<td>11.04 ± 0.37*</td>
</tr>
<tr>
<td>Haematocrit %</td>
<td>38.74 ± 1.56</td>
<td>34.43 ± 1.17</td>
<td>36.57 ± 1.80</td>
<td>33.52 ± 1.11*</td>
</tr>
<tr>
<td>Platelets (10³/µl)</td>
<td>220.70 ± 19.08</td>
<td>219.50 ± 17.86</td>
<td>244.20 ± 15.78</td>
<td>297.70 ± 19.12 a*</td>
</tr>
</tbody>
</table>

*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 all in comparison with the NHV
*P ≤ 0.05 in comparison with Naive

Table 3. Lipid peroxidation and anti oxidants parameters in HIV and HIV-TB patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NHV</th>
<th>Naive</th>
<th>HIV (HAART)</th>
<th>HIV-TB co-infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proteins (mg/ml)</td>
<td>35.53 ± 0.83</td>
<td>54.29 ± 1.35***</td>
<td>37.25 ± 1.83 a</td>
<td>47.13 ± 1.48*** a*</td>
</tr>
<tr>
<td>MDA (nmol/ml)</td>
<td>2.063 ± 0.67</td>
<td>4.403 ± 0.55***</td>
<td>2.325 ± 0.32 a</td>
<td>3.113 ± 0.67b</td>
</tr>
<tr>
<td>GSH (mg/dl)</td>
<td>51.41 ± 6.63</td>
<td>26.83 ± 2.23***</td>
<td>33.62 ± 3.60 b</td>
<td>25.45 ± 3.33***</td>
</tr>
<tr>
<td>SOD (Iu/ml)</td>
<td>5.002 ± 1.95</td>
<td>2.137 ± 0.63</td>
<td>3.364 ± 0.82</td>
<td>2.057 ± 0.67</td>
</tr>
<tr>
<td>CAT (Iu/ml)</td>
<td>43.10 ± 6.99</td>
<td>17.55 ± 4.50 a</td>
<td>31.01 ± 6.12</td>
<td>20.37 ± 5.28</td>
</tr>
<tr>
<td>Vitamin C (mg/dl)</td>
<td>0.567 ± 0.03</td>
<td>0.161 ± 0.04</td>
<td>0.280 ± 0.02 a</td>
<td>0.114 ± 0.03 a</td>
</tr>
</tbody>
</table>

MDA, malondialdehyde; GSH, reduced glutathione; GST, SOD, superoxide dismutase; CAT, catalase. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 all in comparison with the NHV
*P ≤ 0.05 comparison with Naive *P ≤ 0.01 comparison with HIV (HAART)
Discussion

Much research has been conducted in the areas of HIV-TB co-infection, but there few studies in the literature report on oxidative stress markers comparing single infection to co-infection and also comparing the oxidative stress in HIV untreated patients with HIV patients on HAART. This present study was developed to generate data in these areas.

The level of plasma protein in HIV naïve patients was significantly high compared with the HIV patients on HAART. This observation may indicate the chronic inflammatory state of HIV naïve patients which will definitely enhance their state of oxidative stress. Although there was a reduced level of plasma protein in HIV patients on HAART, antiretroviral therapy has also been known to increase chemically reactive species in circulation, possibly by producing more oxidized metabolites deriving from the interaction between ROS and infected-cell biomolecules as reported by Martin et al., [21], Hulgan et al., [22], and Lizette et al., [23]. This argument may be substantiated by the report of Friis-Moller et al. [14], which showed that HIV-infected patients are in oxidative imbalance early in the disease; serum and tissue anti-oxidants levels are low and peroxidation products elevated. Furthermore, the high (P ≤ 0.01) MDA plasma levels in the naïve group could suggest that HIV is a faster generator of free radicals than drugs as evidenced in those untreated patients who are dependent on the body’s immunity alone for defence against infections.

The high level (P ≤ 0.05) of MDA in the HIV-TB co-infection compared with the HIV patients on HAART could be as a result of increased ROS in HIV and TB infections as previously reported in patients with HIV and TB [31-34]. This may further support a role for oxidative stress in the pathogenesis of HIV and TB patients and subsequently suggest a higher rate of viral multiplication and oxidative stress in naïve patients as shown in this study. The correlation between high MDA concentrations and low concentrations of some anti-oxidants suggests increased utilisation by ROS as an important contributing factor to the lower concentrations of anti-oxidants [35]. HIV-infected individuals have been reported to show decreased antioxidant concentrations, disruption in glutathione metabolism, and enhanced spontaneous generation of ROS [36-38]. Apart from the HIV-TB induced oxidative stress, malnutrition may also influence anti-oxidant status and oxidative stress in patients [39]. The present study corroborates the aforementioned as there was a significant decrease (P ≤ 0.01) in the level of vitamin C in the naïve patients as compared with the HIV (HAART) patients. Hence, it appears that suitable exogenous anti-oxidant supplementation may protect these patients from free radical attack and thus be beneficial in their management.

Human monocyte-derived macrophages are involved in a variety of pathological events in HIV infection, the hallmark of which is immunodeficiency with progressive CD4+ T lymphocyte depletion. HIV infections cause a chronic inflammation as shown by high plasma levels of inflammatory cytokines and production of ROS in seropositive individuals. In the present study, there was a statistically significant (P ≤ 0.001) decrease in the level of CD4+ counts in HIV-TB co-infection, HIV patients under treatment, and the ART naïve group when compared to the HIV seronegative normal human volunteers. There was also a decrease (P ≤ 0.05) in the levels of the CD4+ counts in the naïve patients compared with those of the HIV (HAART) and HIV-TB co-infected patients. This observation is an indication of the level of depletion of the host immune system that is often associated with HIV infection. Haematological abnormalities are among the most common complications of infection with HIV [40]. In this study, the red blood cells were significantly (P ≤ 0.001) reduced by the HIV, HIV-TB infections as compared with the levels in the control patients.

Conclusion

The data obtained from this study are sufficient to conclude that there is lower antioxidant potential and higher lipid peroxidation in naïve and HIV-TB co-infected patients as compared to the HIV patients on HAART and the seronegative patients. Thus the general understanding of drug-induced free radical generation may not be absolutely applicable to HIV patients.
management. It may be advisable to always incorporate exogenous antioxidants in the regimen of HIV and HIV-TB co-infected patients.

Acknowledgements

The authors thank the management and staff of the APIN clinic, Lagos University Teaching Hospital, who provided registration, laboratory investigations, and free treatment to all registered HIV patients involved in this study. The authors also thank the participants who volunteered their time for this study.

References


Corresponding author
Awodele Olufunsho, MPH, PhD, FWPC Pharm
Address: Department of Pharmacology
College of Medicine
University of Lagos
PMB12003
Lagos, Nigeria
Telephone: +234-8023624044
Email: awodeleo@yahoo.com

Conflict of interests: No conflict of interests is declared.